Finance Watch: VC Mega-Rounds Are Alive And Well

Venture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting their money into a wide array of start-ups and continuing to support multiple VC mega-rounds of $100m or more, including recent series B rounds totaling $147.5m for Aspen Neuroscience, Inc. and $150m for MOMA Therapeutics.

Aspen Neuroscience plans to take its first autologous cell therapy into the clinic with the proceeds of the financing announced on 5 May. MOMA plans to advance multiple precision oncology...